← 返回

复发性/难治性 B 细胞急性淋巴细胞白血病合并既往脑膜白血病患者中 brexucabtagene autoleucel 相关神经毒性的脑磁共振成像表现

英文原题:Pattern of brexucabtagene autoleucel-related neurotoxicity on magnetic resonance imaging of the brain in a patient with relapsed/refractory B-cell acute lymphoblastic leukemia and prior leptomeningeal disease.

查看英文原题

Pattern of brexucabtagene autoleucel-related neurotoxicity on magnetic resonance imaging of the brain in a patient with relapsed/refractory B-cell acute lymphoblastic leukemia and prior leptomeningeal disease.

PubMed 2023/01/07(内容时间) Radiol Case Rep

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

继发于CAR-T 细胞治疗的免疫效应细胞相关神经毒性综合征(ICANS)在复发/难治性(R/R)B细胞急性淋巴细胞白血病(ALL)成人患者中常见,但该患者人群中神经毒性期间的影像学表现及其意义尚未被系统描述。Brexucabtagene autoleucel(brexu-cel)是一种靶向CD19的自体T细胞免疫疗法,用于治疗R/R B细胞ALL成人患者,可进入中枢神经系统。我们报告一例R/R B细胞ALL且既往有软脑膜病变的成人患者,在接受brexu-cel治疗期间出现神经毒性及脑磁共振成像新发现。我们在临床背景下解读该患者的神经影像学检查,以区分ICANS与残留白血病的活动性治疗。

展开英文摘要原文

Immune effector cell-associated neurotoxicity syndrome (ICANS) secondary to chimeric antigen receptor T-cell therapy is common in adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL), but imaging findings during neurologic toxicity and their meaning have yet to be systematically described in this patient population. Brexucabtagene autoleucel (brexu-cel) is a CD19-directed autologous T-cell immunotherapy for the treatment of adult patients with R/R B-cell ALL that can enter the central nervous system.

We present a case of an adult patient with R/R B-cell ALL and prior leptomeningeal disease who developed neurologic toxicity and new findings on magnetic resonance imaging of the brain while receiving brexu-cel.

We interpret the patient's neuroimaging studies within clinical context to differentiate ICANS from active treatment of residual leukemia.

论文信息

作者
Dean EA、Peters KR、Adams CB、Hiemenz JW
单位
Division of Hematology and Oncology, Department of Medicine, University of Florida, 1515 SW Archer Rd, Gainesville, FL, 32610, USA.United States
文献类型
病例报告
期刊
Radiology case reports2023 Mar
原文标识
PubMed 36660565 · DOI 10.1016/j.radcr.2022.12.053